Business context and reporting period
This is Targacept, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2011, filed November 3, 2011. The request metadata names GYRE Therapeutics, but the filing itself is for Targacept. Targacept is a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor therapeutics; it reported no product sales and depended principally on collaboration revenue, grants, financing and cash reserves.
Financial performance and liquidity
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Operating revenue | $19.0 million | $21.8 million | $78.7 million | $62.2 million |
| Operating expenses | $28.3 million | $19.4 million | $78.3 million | $47.7 million |
| Operating income (loss) | ($9.3 million) | $2.4 million | $0.4 million | $14.5 million |
| Net income (loss) | ($9.1 million) | $2.5 million | $1.3 million | $13.1 million |
| Operating cash flow | Not presented separately | Not presented separately | ($63.2 million) | $154.0 million |
- Q3 diluted loss per share was $0.27; nine-month diluted earnings per share were $0.04.
- Research and development expense was $25.4 million in Q3 and $69.1 million for nine months. Management attributed the increase chiefly to TC-5214 Phase 3 work, TC-6987 trials and AZD3480 Alzheimer’s disease development.
- At September 30, cash, cash equivalents and marketable securities totaled $270.9 million, versus $252.5 million at December 31, 2010. Current assets were $216.8 million and current liabilities $93.6 million, or approximately 2.3 times current-liability coverage.
- Total debt was approximately $3.8 million, including current and long-term portions. No gross margin is reported; the filing presents operating expenses rather than a cost-of-sales measure.
- Nine-month financing cash flow was $83.4 million, including $80.8 million net proceeds from a May/June public stock offering. Investing cash flow was a use of $55.5 million, principally reflecting net investment purchases and equipment spending.
Material changes versus prior comparable periods
- Q3 revenue declined $2.8 million year over year, while expenses increased $8.9 million, turning prior-year quarterly operating income into a loss.
- Nine-month revenue rose $16.5 million, but operating expenses increased $30.5 million and net income fell $11.8 million. Revenue included recognition of $18.4 million of previously deferred GlaxoSmithKline payments following termination of that collaboration, as well as ongoing recognition of AstraZeneca’s TC-5214 upfront payment.
- Nine-month operating cash flow shifted from $154.0 million provided in 2010 to $63.2 million used in 2011. The comparison is substantially affected by the $200 million AstraZeneca upfront payment received in January 2010; it is not a like-for-like measure of underlying cash generation.
- Shareholders’ equity increased to $182.0 million from $91.8 million at year-end 2010, principally reflecting the stock offering. Shares outstanding rose to 33.4 million from 28.9 million.
Outlook, management commentary and risks
- Management expected existing capital resources to fund operations at least through the end of 2014, excluding potential AstraZeneca milestone payments. It cautioned that operating plans and capital needs could change and additional funding might be needed sooner.
- Management expected 2011 R&D expense to exceed 2010, citing TC-5214 Phase 3, two TC-6987 Phase 2 studies, AZD3480 Alzheimer’s disease work and preparation for additional TC-5619 trials.
- TC-5214 was being developed with AstraZeneca for major depressive disorder. Targacept shared 20% of initial-program costs; favorable Phase 2b results still needed replication in Phase 3, and regulatory approval and future milestone or royalty revenue were uncertain.
- GlaxoSmithKline’s collaboration termination became effective in late May 2011. AstraZeneca had declined its option to license TC-5619 in April 2011. Management did not then expect further AstraZeneca development of AZD3480 for ADHD, citing concern about the therapeutic margin; an AZD3480 Alzheimer’s disease study began in October 2011. AstraZeneca was expected to decide on AZD1446 advancement in Q4 2011.
- Risks include clinical-trial outcomes and delays, reliance on AstraZeneca’s development decisions and payments, regulatory uncertainty, uncertain future financing and potential dilution. The company had an accumulated deficit of $217.1 million. Management reported disclosure controls effective and no material quarterly change in internal control over financial reporting.
Most important facts for investors to verify
- Progress, timing and results of TC-5214 Phase 3 trials, and the related cost-sharing burden and milestone conditions.
- Whether reported cash resources and management’s end-of-2014 runway estimate remain adequate as development spending increases.
- AstraZeneca’s AZD1446 advancement decision and funding/payment milestones for AZD3480 Alzheimer’s disease work.
- How much reported revenue reflects deferred collaboration payments rather than recurring activity, and whether any future milestones are achieved.
- Potential limits on use of tax-loss and credit carryforwards, including ownership-change restrictions, and the outcome of North Carolina tax examinations.